384 related articles for article (PubMed ID: 12562576)
1. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
[TBL] [Abstract][Full Text] [Related]
2. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
Poyurovsky M; Fuchs C; Pashinian A; Levi A; Faragian S; Maayan R; Gil-Ad I
Psychopharmacology (Berl); 2007 Jun; 192(3):441-8. PubMed ID: 17310385
[TBL] [Abstract][Full Text] [Related]
3. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
[TBL] [Abstract][Full Text] [Related]
4. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.
Amrami-Weizman A; Maayan R; Gil-Ad I; Pashinian A; Fuchs C; Kotler M; Poyurovsky M
Psychopharmacology (Berl); 2013 Nov; 230(1):23-7. PubMed ID: 23828160
[TBL] [Abstract][Full Text] [Related]
5. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
6. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
Poyurovsky M; Faragian S; Fuchs C; Pashinian A
Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A
Am J Psychiatry; 2002 Jun; 159(6):1058-60. PubMed ID: 12042201
[TBL] [Abstract][Full Text] [Related]
8. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
Poyurovsky M; Tal V; Maayan R; Gil-Ad I; Fuchs C; Weizman A
Eur Neuropsychopharmacol; 2004 Aug; 14(4):332-6. PubMed ID: 15163444
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
10. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
11. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.
Atmaca M; Kuloglu M; Tezcan E; Ustundag B
Hum Psychopharmacol; 2003 Aug; 18(6):457-61. PubMed ID: 12923824
[TBL] [Abstract][Full Text] [Related]
12. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
14. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
15. Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.
Pae CU; Kim JJ; Lee KU; Lee CU; Bahk WM; Lee SJ; Lee C; Paik IH
Hum Psychopharmacol; 2003 Aug; 18(6):453-6. PubMed ID: 12923823
[TBL] [Abstract][Full Text] [Related]
16. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
[TBL] [Abstract][Full Text] [Related]
19. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
20. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.
Bustillo JR; Lauriello J; Parker K; Hammond R; Rowland L; Bogenschutz M; Keith S
Neuropsychopharmacology; 2003 Mar; 28(3):527-9. PubMed ID: 12629532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
